Seagen and zai lab announce regional strategic collaboration and license agreement for tivdak® (tisotumab vedotin-tftv)

Bothell, wash. & shanghai & cambridge, mass.--(business wire)--seagen inc. (nasdaq: sgen), a world leader and pioneer in antibody-drug conjugate (adc) therapies, and zai lab limited (nasdaq: zlab; hkex: 9688), a patient-focused, innovative, commercial-stage global biopharmaceutical company, today announced an exclusive collaboration and license agreement for the development and commercialization of tivdak® (tisotumab vedotin-tftv) in mainland china, hong kong, macau, and taiwan. tivdak is the f
SGEN Ratings Summary
SGEN Quant Ranking